Новые возможности применения бета-адреноблокаторов: особые свойства карведилола


Напалков Д.А., Сеидова Н.М.

Первый МГМУ им. И.М. Сеченова, Москва
Обсуждаются особенности механизмов действия и показания к применению карведилола. Рассматриваются его фармакологические свойства, не связанные непосредственно с бета-адреноблокирующим действием. У карведилола обнаружены эффекты периферического вазодилататора, обусловленные сопутствующим антагонизмом к альфа1-адренорецепторам. Его особенностью является также способность связывать образующиеся свободные радикалы (эффект "ловушки"). Приведены данные контролируемых клинических исследований, в которых оценивали эффективность и безопасность карведилола.

Литература


1. Arumanayagam M, Chan S, Tong S, et al. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. J Cardiovasc Pharmacol 2001;37:48–54.


2. Bloomfield DM, Steinman RS. Microvolt T Wave Alternans Distinguishes. Between Patients Likely and Patients Not Likely to Benefit From Implanted. Cardiac Defibrillator Therapy. Circulation. 2004;110: 1885–89.


3. CHRISTMAS: principal results. Basel, F.Hoffman La Roche Ltd. 2002;15.


4. COMET: principial results. F. Hoffman La Roche Ltd., Bazel. 2003;5.


5. Costantini O, Hohnloser SH, Kirk MM, et al. The Alternans Beforе Cardioverter Defibrillator (ABCD) trial. J Am Coll Cardiol 2009;53:471–79.


6. Feuerstein G, Yue TL, Ma Xo L, et al. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Progr Cardiovasc Dis 1998;41(1):17–24.


7. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure. A Report From the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007;50:768–77.


8. Gao F, Chen J, Lopez BL, et al. Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol 2000;406:109–16.


9. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin dependent diabetes mellitus and hypertension. A randomised controlled trial. Ann Intern Med 1997;126:955–59.


10. Gress T, Nieto F, Shahar E, et al. Hypertension and antihyperten-sive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905–12.


11. Jakob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two betablocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996;14:489–94.


12. Khand AU, Rankin AC, Martin W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003;42:1944–51.


13. Klingenheben T, Gronefeld G, Li YG, et al. Effect of metoprolol and d,l-sotalol on microvoltlevel T-wave alternans. Results of a prospective, double-blind, randomized study. J Am Coll Cardiol 2001;38:2013.


14. Lowes BD, Gill EA, Abraham WT, et al. Effects of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure. Am J Cardiol 1999; 83:1201–05.


15. Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of meta-analysis. Am Heart J 2001;141:899–907.


16. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349–55.


17. Remme WJ. Should ACE inhibition always be first-line therapy in heart failure? Lessons from the CARMEN study. Cardiovasc Drugs Ther 2003;17:107–09.


18. Watanabe H, Kakihana M, Ohtsuka S, et al. Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with congestive heart failure. J Am Coll Cardiol 1998;32(5):1468.


19. Weber K, Bohmeke T, Van Der Does R, et al. Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Cardiovasc Drugs Ther 1996;10:113–17.


20. Weglicki WD. The antioxidative and antiproliferative effects of carvedilol. Beringer Mannheim GmbH Ed. 1994;31.


21. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect of survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS III). Circulation 2005;12:2426–35.


22. Yue TL, Wang X, Gu JL, et al. Carvedilol, a new vasodilating (β-adrenoreceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leucocyte adhesion to smooth muscle cells. JPharmacolExpTher 1995;273:1442–49.


23. Подзолков В.И., Напалков Д.А., Винниченко О.Н. Карведилол – эффективное средство лечения сердечной недостаточности и артериальной гипертензии // Фарматека 2007. № 101(6). С. 27.


24. Преображенский Д.В, Сидоренко Б.А., Дедова И.С. и др. Блокаторы β-адренорецепторов в лечении сердечнососудистых заболеваний: место карведилола // Кардиология 2006. № 12. С. 63–72.


Похожие статьи


Бионика Медиа